Diplomat Pharmacy Inc (DPLO) Receives Consensus Recommendation of “Hold” from Analysts
Diplomat Pharmacy Inc (NYSE:DPLO) has received a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $26.67.
Several equities analysts have commented on DPLO shares. Leerink Swann reiterated an “outperform” rating and issued a $33.00 price target on shares of Diplomat Pharmacy in a research note on Friday, June 22nd. ValuEngine upgraded shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research report on Saturday, June 16th. Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 9th. JPMorgan Chase & Co. upgraded shares of Diplomat Pharmacy from a “neutral” rating to an “overweight” rating in a research report on Thursday, May 10th. Finally, Morgan Stanley raised their target price on shares of Diplomat Pharmacy from $16.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 3rd.
In other news, Director Jeffrey G. Park sold 13,875 shares of the firm’s stock in a transaction that occurred on Wednesday, May 23rd. The shares were sold at an average price of $24.20, for a total transaction of $335,775.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Shawn Tomasello sold 1,680 shares of the firm’s stock in a transaction that occurred on Tuesday, June 5th. The stock was sold at an average price of $24.27, for a total transaction of $40,773.60. Following the transaction, the director now owns 12,816 shares in the company, valued at $311,044.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,250 shares of company stock worth $419,364. Insiders own 24.70% of the company’s stock.
Shares of Diplomat Pharmacy stock opened at $19.05 on Friday. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of 22.68 and a beta of 1.14. Diplomat Pharmacy has a 52 week low of $14.50 and a 52 week high of $28.74. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.63 and a current ratio of 0.91.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, August 6th. The company reported $0.17 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by ($0.06). The company had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.42 billion. Diplomat Pharmacy had a net margin of 0.06% and a return on equity of 7.86%. The business’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.25 earnings per share. analysts anticipate that Diplomat Pharmacy will post 0.87 EPS for the current fiscal year.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Recommended Story: Fundamental Analysis
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.